Merck (MRK) may be a storied pharmaceutical giant with a 134-year history, but it still has a lot of room to run. Merck is ...

Moderna Inc. shares declined as the company’s cost-cutting efforts failed to assuage investors who are worried about the ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. The company has a strong ...

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...

A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory ...

- Non-GAAP EPS of $2.13 topped estimates by $0.11 in Q2 2025; GAAP revenue of $15.8 billion missed by $93 million in Q2 2025. - KEYTRUDA oncology drug sales climbed 9% in Q2 2025, while GARDASIL ...

“Our study findings emphasize the importance of addressing the burden of RSV-related hospitalizations through effective prevention measures,” the researchers noted. Disclosure: This study was ...

HHS Secretary Robert F. Kennedy Jr. formally accepted recommendations that would require all vaccine manufacturers to ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

The federal government is recommending flu vaccines remove the preservative thimerosal after Health and Human Services ...

Merck & Co., Inc. (NYSE:MRK) further mentioned that the typical RSV season generally spans autumn to spring of the next year.